ReviewCellular and molecular life sciences : CMLS2026
Game of clones: decipher lineage plasticity in hormone-driven cancers.
Review in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Great Escape: the systems biology of endocrine resistance and lineage plasticity.Endocrine-related cancer · 2026Review
- Advances in Mechanism of Action and Efficacy of CBP/p300 Inhibitors in Different Subtypes of Breast Cancer.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hormone-dependent cancers such as prostate, breast, and endometrial carcinomas rely on nuclear hormone receptors to sustain lineage identity and growth. Therapies targeting androgen, estrogen, or progesterone signaling are initially effective but ultimately impose selective pressures that drive resistance through lineage plasticity, the ability of tumor cells to abandon their native identity and adopt alternative cellular fates. While the biological consequences of lineage plasticity are increasingly recognized, a major challenge lies in defining the regulatory programs that govern these cell fate transitions and determine their stability, directionality, and therapeutic vulnerability. In this review, we focus on the regulatory modules that underlie lineage plasticity in hormone-driven cancers. We highlight how integrative multi-omics approaches spanning genomic, transcriptomic, epigenomic, proteomic, and chromatin-level layers have enabled the identification of transcriptional and epigenetic programs that destabilize lineage fidelity. We discuss how single-cell and spatial technologies have revealed intermediate states, rare subpopulations, and microenvironmental influences that shape plasticity trajectories. Finally, we emphasize the role of artificial intelligence and machine learning as integrative tools to reconstruct gene regulatory circuits, infer fate transitions, and connect molecular programs to phenotypic outcomes. By synthesizing these biological insights across experimental and computational modalities, we propose a conceptual framework for understanding lineage plasticity in hormone-driven cancers, with emphasis on prostate and breast malignancies. This integrated perspective highlights how regulatory programs governing cell identity can be revealed, perturbed, and potentially constrained, offering opportunities to identify biomarkers, expose therapeutic vulnerabilities, and ultimately translate mechanistic understanding into strategies that limit resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.